A Randomised, Double-Blind, Parallel-Group, Flexible-Dose Study Exploring the Neurocognitive Effect of Sertindole Versus Comparator in Patients With Schizophrenia Using the MATRICS Consensus Cognitive Battery (MCCB).

Trial Profile

A Randomised, Double-Blind, Parallel-Group, Flexible-Dose Study Exploring the Neurocognitive Effect of Sertindole Versus Comparator in Patients With Schizophrenia Using the MATRICS Consensus Cognitive Battery (MCCB).

Completed
Phase of Trial: Phase III

Latest Information Update: 13 Sep 2013

At a glance

  • Drugs Quetiapine; Sertindole
  • Indications Schizophrenia
  • Focus Therapeutic Use
  • Sponsors Lundbeck A/S
  • Most Recent Events

    • 05 May 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 27 Jan 2010 Actual patient number (264) added as reported by ClinicalTrials.gov.
    • 27 Jan 2010 Planned end date changed from 1 Feb 2010 to 1 Mar 2010 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top